SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced that its DISCOVER CE Mark Trial met its primary mortality endpoint. The study also demonstrated that greater than 95 percent of patients had mild or less aortic regurgitation, and no patients experienced vascular complications. The DISCOVER Trial results were presented yesterday at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Miami, Florida.
